gms | German Medical Science

130. Kongress der Deutschen Gesellschaft für Chirurgie

Deutsche Gesellschaft für Chirurgie

30.04. - 03.05.2013, München

ATG modulates the endothelial activity and immune cell adhesion

Meeting Abstract

  • Andres Beiras-Fernandez - Klinikum JW Goethe Universität, Thorax und Herzchirurgie, Frankfurt
  • Edin Srndic - Klinikum JW Goethe Universität, Thorax und Herzchirurgie, Frankfurt
  • Ulrich Stock - Klinikum JW Goethe Universität, Thorax und Herzchirurgie, Frankfurt
  • Isabella Kanzler - Klinikum JW Goethe Universität, Thorax und Herzchirurgie, Frankfurt

Deutsche Gesellschaft für Chirurgie. 130. Kongress der Deutschen Gesellschaft für Chirurgie. München, 30.04.-03.05.2013. Düsseldorf: German Medical Science GMS Publishing House; 2013. Doc13dgch845

doi: 10.3205/13dgch845, urn:nbn:de:0183-13dgch8453

Veröffentlicht: 26. April 2013

© 2013 Beiras-Fernandez et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen ( Er darf vervielfältigt, verbreitet und öffentlich zugänglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.



Introduction: ATG-Fresenius, a highly purified rabbit polyclonal anti-human T-lymphocyte immunoglobulin resulting from immunisation of rabbits with the Jurkat T-Lymphoblast cell line is currently used for the prevention of acute rejection in patients receiving solid organ-transplants. The aim of this study was to investigate the in vitro activity of ATG-Fresenius that underlies its activity in prevention of ischemia-reperfusion injury in solid organ transplantation.

Material and methods: Human vascular endothelial cells (HUVEC) and peripheral blood mononuclear cells (PBMCs) were isolated from umbilical vein or peripheral blood, incubated 20 to 24 h before analysis of adhesion molecule expression and use in the ATG Fresenius-binding or immune cell adhesion assays. The cells were cultured alone or activated with TNF-alpha (HUVECs) or phytohaemagglutinin (PBMCs) for 20 h. HUVEC were incubated for 30 min at 2-8ºC with 10 and 100 mg/mL ATG-Fresenius (Fresenius Biotech GmbH) or reference rabbit IgG (Fresenius Biotech GmbH). Analysis of adhesion of immune cells to endothelial cells used co-cultures of peripheral blood mononuclear cells (PBMC) and adherent HUVEC. Endothelial cell expression of the adhesion molecules CD62E and CD54 was determined by flow-cytometry. The relative amounts of T-, B- and NK-cells attached to HUVEC were also determined by flow cytometry (FACSCalibur). T cells were identified by CD3 expression, B-cells by CD19 expression, NK-cells by CD16 expression, and HUVEC by CD31 expression. Groups were compared using one-way analysis of variance (ANOVA) and Tukey-Kramer multiple comparison test

Results: We show that ATG-Fresenius binds to endothelial cells, with a higher level of binding to activated endothelial cells that express increased levels of E-selectin and ICAM-1. The increased binding of ATG-Fresenius to cytokine-activated endothelial cells is consistent with its known binding to ICAM-1 and selectins. We also show that ATG-Fresenius inhibits adhesion of prestimulated immune cells to activated endothelium.

Conclusion: Our in vitro results provide a rationale supporting of pre-reperfusion administration of ATG-Fresenius in solid organ transplantation.